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Abstract
Background: Microbial contamination of pharmaceuticals poses a great problem to the pharmaceutical
manufacturing process, especially from a medical as well as an economic point of view. Depending upon the
product and its intended use, the identification of isolates should not merely be limited to the United States
Pharmacopeia (USP) indicator organisms.
Results: Eighty-five pre-used non-sterile pharmaceuticals collected from random consumers in Egypt were
examined for the eventual presence of bacterial contaminants. Forty-one bacterial contaminants were isolated from
31 of the tested preparations. These isolates were subjected to biochemical identification by both conventional
tests as well as API kits, which were sufficient for the accurate identification of only 11 out of the 41 bacterial
contaminants (26.8 %) to the species level. The remaining isolates were inconclusively identified or showed
contradictory results after using both biochemical methods. Using molecular methods, 24 isolates (58.5 %) were
successfully identified to the species level. Moreover, polymerase chain reaction (PCR) assays were compared to
standard biochemical methods in the detection of pharmacopoeial bacterial indicators in artificially-contaminated
pharmaceutical samples.
Conclusion: PCR-based methods proved to be superior regarding speed, cost-effectiveness and sensitivity.
Therefore, pharmaceutical manufacturers would be advised to adopt PCR-based methods in the microbiological
quality testing of pharmaceuticals in the future.
Keywords: Pharmaceutical contaminants, Biochemical identification, Molecular identification, Artificial
contamination, Minimum detection limit
Background
Microbial contamination of pharmaceuticals has been an
everlasting problem for researchers as well as pharma-
ceutical manufacturers worldwide. It can result in the
spoilage of the formula by breaking down active ingredi-
ents and excipients, affecting the potency, stability and
efficacy of the drug [1]. Furthermore, the presence of
high numbers of pathogens poses a serious health threat
to consumers, especially those who are already ill or in a
weakened state [1–3]. Several cases of infection due to
contaminated pharmaceuticals were reported in litera-
ture [4–6].
Common pharmaceutical contaminants include bac-
teria, where contamination with Gram-positive bacteria
implicates human intervention as a major reason for
product contamination, while the presence of Gram-
negative bacteria suggests lack of process control in
pharmaceutical environments, especially involving water
systems and raw materials [4]. Gram-negative rods are
considered the most commonly found bacterial isolates
in non-sterile pharmaceuticals, regardless of geograph-
ical location or time [4, 7].
Conventional standard microbiological methods are
currently used for the routine testing of pharmaceutical
products and identification of pharmaceutical bacterial
contaminants, including conventional pharmacopoeial
methods, as well as simplified, commercially available
biochemical test kits, such as the API system [8, 9]. Re-
cently, however, molecular technologies have positively af-
fected the field of pharmaceutical microbiology, providing
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rapid quantitative as well as qualitative information on mi-
croorganisms present in a given pharmaceutical sample
[10–12]. The 16S rRNA gene is most commonly used for
taxonomic purposes [13, 14].
The objective of this study was to identify bacterial
contaminants, isolated from different pharmaceuticals
using conventional biochemical methods and the API
identification system. Bacterial isolates showing incon-
clusive or contradictory results were further subjected to
polymerase chain reaction (PCR)-based methods of
identification using either universal or species-specific
primer pairs.
Moreover, this study aimed at comparing between
standard biochemical methods and PCR-based assays in
the detection of pharmacopoeial bacterial indicators in
artificially-contaminated pharmaceutical samples with
respect to time, cost and limit of detection.
Methods
Standard bacterial strains
The following standard strains were used: Staphylococ-
cus aureus ATCC 6538P, Staphylococcus epidermidis
ATCC 12228, Bacillus subtilis ATCC 6633, Bacillus ce-
reus ATCC 14579, Escherichia coli NCTC 10418, Klebsi-
ella pneumoniae ATCC 13883, Salmonella enterica
subspecies enterica ATCC 14028, and Pseudomonas aer-
uginosa ATCC 9027.
Tested pharmaceuticals
A total of 85 used pharmaceuticals (taken after verbal
consent from the consumers) were tested for bacterial
contamination. These included 28 pharmaceutical prepa-
rations, 33 cosmetic preparations, 17 raw materials and
7 herbal products.
Isolation of contaminants
One gram (or 10 ml) of the tested pharmaceutical were
aseptically added to 20 ml of sterile tryptic soy broth
(TSB) with or without PLT (polysorbate-20 5 % v/v, leci-
thin 0.3 % w/v, thioglycolate 0.01 % w/v) as a neutraliz-
ing agent [15] and incubated at 37 °C for 24–48 h in a
shaking incubator at 110 rpm. Fifty microliters (μl) ali-
quots of the overnight cultures were then streaked onto
nutrient agar plates and incubated at 37 °C for 24 h.
Identification of the bacterial isolates by biochemical tests
After Gram-staining, the bacterial isolates were identified
according to the “Identification flow charts” of Bergey’s
Manual of Determinative Bacteriology [16].
The Gram-positive cocci were streaked onto the
surface of mannitol salt agar (MSA), and then identi-
fied by subjecting them to confirmatory tests specific
for Staphylococcus spp., including catalase test, tube
coagulase test, DNase test, blood hemolysis, urease test
and novobiocin sensitivity test. The tested isolates were
further identified using the API Staph kit (BioMérieux,
France) according to the manufacturer’s instructions.
Sporulating, rod-shaped Gram-positive isolates were sub-
jected to spore staining to confirm the presence of Bacil-
lus spp. They were subsequently subjected to biochemical
tests, namely starch hydrolysis (test for amylase), Voges
Proskauer and catalase tests [16–19].
On the other hand, Gram-negative isolates were re-
spectively streaked onto the surface of both MacConkey’s
agar and cetrimide agar. Oxidase-negative Gram-negative
isolates, growing only on MacConkey’s agar (enterobac-
teria) were further identified using various biochemical
tests including indole production, methyl red, Voges
Proskauer, citrate utilization, urease, oxidative/fermenta-
tive activity, motility tests as well as growth on triple sugar
iron agar and xylose lysine desoxycholate agar [17, 20, 21].
Further biochemical identification of Gram-negative
isolates was done using the API 20E kit (BioMérieux,
France).
PCR-based identification
Identification using species-specific primer pairs
PCR-based identification of a specific bacterial species
was carried out using a DNA extraction protocol [22],
and the species-specific primer pairs were designed using
the Standard Nucleotide Basic Local Alignment Search
Tool (BLAST) [23]. The adopted species-specific primer
pairs and universal primer pairs are listed in Table 1.
Six species-specific primer pairs for S. hominis, S. war-
neri [24], S. epidermidis [25], B. subtilis, B. cereus and B.
anthracis [26] were used for further identification of se-
lected staphylococcal and Bacillus isolates, respectively,
by a simple uniplex PCR-based method. Appropriate
positive and negative controls were included to exclude
false negative and false positive results [27]. The primers
for S. epidermidis ATCC 12228, S. warneri isolate (36),
B. subtilis ATCC 6633 and B. cereus ATCC 14579 were
used as the positive controls for their respective strains,
whereas the 16S rRNA universal primer pair was used as
a positive control for S. hominis and B. anthracis. On
the other hand, S. aureus ATCC 6538P was used as the
negative control for S. epidermidis, S. warneri and S.
hominis. In addition, B. cereus ATCC 14579 was used as
a negative control for B. subtilis while B. subtilis ATCC
6633 acted as a negative control for B. cereus and B.
anthracis.
The protocol of amplification for all of the tested bac-
terial species was as follows: 12.5 μl of 2× Green PCR
master mix (DreamTaq™, Fermentas Life Sciences,
France), 5 μl DNA template (10 pg-1 μg), 0.4 μM of each
primer, and 5.5 μl PCR-grade water.
The PCR reactions were performed using a Perkin
Elmer thermocycler (Gene Amp PCR system 2400,
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USA), with an initial denaturation at 95 °C for 5 min,
followed by 30 cycles at 95°C (0.5 min), Tm-5 (0.5 min)
and 72 °C (0.5-1.5 min) and a final extension at 72 °C
for 10 min. The extension time during the 30 cycles was
chosen based on the product size (1 min/kb).
The amplified samples were then analyzed by agarose
gel electrophoresis using 1–1.5 % agarose gels (Fischer
Scientific®, UK) that had been prestained with ethidium
bromide (Fischer Scientific, Canada).
Identification using 16S rRNA universal primer pair
Identification of selected bacterial isolates was done by
PCR amplification of the16S rRNA gene using universal
primer pair [28, 29], followed by 16S rRNA gene
Table 1 PCR primers used in this study
Bacterial target/Primer
name
Forward (F) and Reverse (R) primer
Annealing temperature (tm-5 °C)
Nucleo-tide
positionsa
Gene amplified PCR product
size (bp)
Ref.
Universal primer pair F: 5′AGAGTTTGATCMTGGCTCAG3′ NP 16S rRNA 1500 [27]
R: 5′TACGGYACCTTGTTACGACTT3′
(46.8 °C)
S. hominis F: 5′GTTCGATAGTGAAAGATGGCTC3′ NP 16S rRNA 833-852 [24]
R: 5′GGAAACTTCTATCTCTAGAAGG3′
(43.4 °C)
S. warneri F: 5′GGTTCAATAGTGAAAGGCGGC3′ NP 16S rRNA 833-852 [24]
R: 5′GGAAGACTCTATCTCTAGAGC3′
(41.1 °C)
S. epidermidis F: 5′
TCTCTTTTAATTTCATCTTCAATTCCATAG3′





B. anthracis F: 5′AATCGTAATATTAAACTGACG3′ 607-627 gyrB 244 [26]
R: 5′CCTTCATACGTGTGAATGTTG3′ 831-851
(40.5 °C)
B. cereus F: 5′ATTGGTGACACCGATCAAACA3′ 490-510 gyrB 364 [26]
R: 5′TCATACGTATGGATGTTATTC3′ 834 -854
(41 °C)
B. subtilis F:5′CAGTCAGGAAATGCGTACGTC CTT3′ NP gyrA 1027 [26]
R:5′CAAGGTAATGCTCCAGGCATTGCT3′
(57.2 °C)
S. aureus F: 5′GCGATTGATGGTGATACGGTT3′ 48-70 nucA (nuclease A) 280 [32]
R: 5′AGCCAAGCCTTGACGAACTAA AGC3′ 303-328
(55 °C)
E. coli F: 5′AAAACGGCAAGAAAAAGCAG3′ 754-773 uidA (β-D-glucuro-nidase) 147 [31]
R: 5′ACGCGTGGTTACAGTCTTGCG3′ 880-900
(50.7 °C)
S. enterica F: 5′ATCGCCACGTTCGGGCAATTC3′ NP invA (invasion protein) 275 [33]
R: 5′ACGGTTCCTTTGACGGTGCGAT3′
(55 °C)






aNucleotide positions: refers to the positions of the nucleotides on the target gene where the forward and reverse primers anneal
bA genomic DNA fragment with unknown coding potential
NP Not Provided
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sequencing of the amplified PCR products. Genomic
bacterial DNA isolation kit (Biospin Bacteria Genomic
DNA Extraction Kit, Cat# BSC12S1, China) was used to
extract highly pure DNA, which was used for down-
stream molecular experiments, including DNA sequen-
cing. Each PCR reaction tube (final volume, 50 μl)
contained the following: 25 μl of 2× Green PCR master
mix (DreamTaq™, Fermentas Life Sciences, France), 7 μl
DNA extract (10 pg-1 μg), 0.6 μΜ of each primer, and
12 μl PCR-grade water. A negative control was prepared
by replacing the DNA template with sterile deionized
water (DiW). The PCR reaction was performed with an
initial denaturation at 95 °C for 5 min, followed by 30
cycles at 95 °C, 46.8 °C and 72 °C for 0.5 min, 0.5 min
and 1.5 min, respectively and a final extension at 72 °C
for 10 min. The final PCR product was purified by the
company Sigma for Scientific Services (Cairo, Egypt)
prior to DNA sequencing of the 16S rRNA gene with the
help of a Bioneer automated sequencer (Bioneer 3730xl,
USA), using forward and reverse 16S rRNA universal
primer pairs [28, 29].
Sequence alignments and construction of phylogenetic
trees
Using the Nucleotide Basic Local Alignment Search Tool
(BLAST) [30], the nucleotide sequences were compared
against the GenBank database. The top twenty homology
matched hits for each isolate, with the highest total
score, were then used together with the isolate sequence
to construct a phylogenetic tree using the BLAST
program.
Artificial contamination of a pharmaceutical sample
Ten-gram samples of raw material glucose powder were
added to 100 ml of TSB. After thorough dissolution,
samples were inoculated separately with 1 ml of a 10−6
dilution of 24-h TSB cultures of either P. aeruginosa
ATCC 9027, E. coli NCTC 10418, S. aureus ATCC
6538P or S. enterica subsp. enterica ATCC 14028. Inocu-
lated samples were placed in a shaking incubator for 24 h
at 37 °C and 100 rpm.
Standard methods for isolation and detection of bacterial
contaminants
After incubation, the enriched TSB cultures were
streaked on MacConkey’s agar, MSA, cetrimide agar and
Xylose-Lysine-Desoxycholate (XLD) agar plates. After
incubation at 37 °C for 24–48 h, colonies were streaked
onto sterile plates of trypticase soy agar (TSA) for isola-
tion of pure cultures. TSA plates were incubated for 18–
24 h and cells from pure cultures were Gram-stained
and then subjected to biochemical identification tests.
Additionally, API 20E and API Staph kits were used for
further biochemical identification.
DNA extraction from artificially-contaminated samples
Three ml-aliquots of the artificially-contaminated sam-
ples were centrifuged for 10 min at 14000 rpm. The pel-
let was washed twice in 1 ml of sterile DiW, then
resuspended in 1 ml of sterile DiW and boiled for 10–15
min followed by centrifugation at 14000 rpm for 5 min.
The supernatant was used as a source of DNA for the
PCR reaction.
PCR detection of bacterial contaminants
For each sample, 10 μl of the DNA lysate (10 pg-1 μg)
were transferred into a PCR tube containing 12.5 μl 2×
Green PCR master mix (DreamTaq™, Fermentas Life
Sciences, France), 0.4 μM of each primer (Table 1), and
0.5 μl PCR-grade water. The simple uniplex PCR reac-
tion conditions were optimized for the different species-
specific primer pairs for each bacterial contaminant [28,
29, 31–33], so that they could be used in a single PCR
run with an initial denaturation at 95 °C for 5 min,
followed by 40 cycles at 95 °C, 55 °C and 72 °C for 0.5
min, 0.5 min and 0.75 min, respectively, and a final ex-
tension at 72 °C for 10 min.
Determination of Minimum Detection limit (MDL) for both
methods under investigation
The MDL of each method was determined by using
standard E. coli NCTC 10418 as a representative of bac-
terial contaminants. The pharmaceutical product used
was 10 % glucose solution prepared aseptically by adding
10 gm glucose powder to 100 ml sterile distilled water.
A TSB culture of E. coli NCTC 10418 was diluted in
0.9 % sterile saline to prepare a series of 10-fold dilu-
tions. The 10 % glucose solutions were separately inocu-
lated with the above mentioned dilutions to contain
about 107 - 102 CFU/ml for each of the tested
methods. To determine the MDL for conventional bio-
chemical methods; a loopful of each inoculated sample
was streaked onto selective media (MacConkey’s agar
and XLD agar) as well as TSA plates. The MDL was
estimated based on the least inoculum (CFU/ml of
the sample) showing growth on agar plates.
To determine the MDL for PCR-based methods, the
following was done: 1ml of each inoculated sample was
centrifuged at 14000 rpm for 10 min. The supernatant
was discarded and the pellet was resuspended in 5 μl
sterile DiW which was then transferred into a PCR tube
that was then heated at 95 °C for 10 min to extract
DNA. The remaining PCR components were then added
to the PCR tube: 12.5 μl of 2× Green PCR master mix
(DreamTaq™, Fermentas Life Sciences, France), 0.4 μM
of each primer, and 5.5 μl PCR-grade water.
Using the species-specific primer pair for E. coli
[29, 31], the reaction was performed with an initial
denaturation at 95 °C for 5 min, followed by 30 cycles at
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95°C, 50.7°C and 72°C for 0.5 min each, and a final exten-
sion at 72°C for 10 min.
Results
A total of 85 pre-used pharmaceuticals (Additional file 1)
were collected and examined for the eventual presence of
bacterial contaminants. The samples were collected from
different available classes of preparations including syrups,
elixirs, drops (eye, ear and oral), powders, teabags and cos-
metics. In total, 41 bacterial contaminants were success-
fully isolated from 31 of the tested pharmaceuticals, i.e.,
bacterial contaminants were found in 36.5% of the tested
products. These contaminants were distributed as follows:
9 from 28 pharmaceutical preparations, 10 from 17 raw
materials, 12 from 33 cosmetic preparations and 10 from 7
herbal products. Gram-positive bacteria were more preva-
lent than Gram-negative bacteria in the tested products,
where they constituted 88.9% (8/9), 91.7% (11/12) and
100% (10/10) of the detected contaminants in pharmaceut-
ical preparations, cosmetic preparations and raw materials,
respectively. On the other hand, 9 out of the 10 contami-
nants in herbal products were Gram-negative bacteria.
Following their isolation, the bacterial contaminants
were subjected to biochemical identification, using conven-
tional tests as well as API identification systems. Selected
isolates, which showed inconclusive or contradictory re-
sults, were further identified using PCR-based methods.
Biochemical identification of the bacterial isolates
Among the isolated contaminants, 30 isolates were
Gram-positive (12 coagulase-negative staphylococci, 16
Bacillus spp., one Kocuria/Micrococcus spp. and one
Gram-positive non-spore-forming rod), whereas the
remaining 11 isolates were thin short Gram-negative
rods (10 enterobacterial isolates and one Pseudomonas
spp.).
Based on the biochemical identification results of the
13 Gram-positive cocci (Table 2), six isolates were accur-
ately identified by both conventional methods and the
API Staph system. On the other hand, the remaining 7
isolates and the Gram-positive, non-spore-forming, rod-
shaped isolate 24B were not conclusively identified, and
were thus further subjected to PCR-based methods to
achieve proper identification.
The Bacillus contaminants, representing 39% of the
isolated contaminants, were isolated from the tested raw
materials, and their identity was confirmed by differen-
tial biochemical tests, including starch hydrolysis, Voges
Proskauer and catalase tests (Additional file 2).
Based on the biochemical identification results of the
11 Gram-negative isolates (Table 3), only five were con-
clusively identified using both conventional methods and
the API 20E system.
Molecular identification using PCR-based methods
Species-specific primer pairs were used whenever the re-
sults of the conventional and the API methods were
contradictory, or when further identification to the spe-
cies level was required. This pertained to 5 staphylococ-
cal isolates (17, 20A, 44, 52 and 62; Table 1), as well as
all of the Bacillus isolates. Two of the former isolates
(20A and 52) showed a PCR product at the specified





Identification based on API Staph kit Final conclusion
Result (%ID) Level of discrimination
16A S. epidermidis S. epidermidis (95.3 %) Good S. epidermidisa
16B S. hominis, S. cohnii, S. saprophyticus,
S. xylosus, S. simulans or S. warneri
S. saprophyticus (64.6 %) Not valid b
17 S. warneri (61.5 %), S. hominis (35.5 %) Good to genus S. warneri or S. hominisc
20A S. epidermidis S. auricularis (83.9 %) Good to genus d
20B S. epidermidis S. epidermidis (96.1 %) Good S. epidermidisa
22 S. epidermidis S. hominis (46 %), S. warneri (21.3 %) Not valid b
23 S. haemolyticus S. haemolyticus (88.9 %) Acceptable S. haemolyticusa
24A Micrococcus spp. Kocuria varians/rosea (97.8 %) Good Kocuria variansa
36 S. hominis, S. cohnii, S. saprophyticus,
S. xylosus, S. simulans or S. warneri
S. warneri (89.9 %) Good to genus S. warneria
44 S. warneri (61.5 %), S. hominis (35.5 %) Good to genus S. warneri or S. hominisc
52 S. epidermidis S. chromogenes (72.2 %) Good to genus d
57A S. epidermidis S. epidermidis (98.1 %) Good S. epidermidisa
62 S. hominis, S. cohnii, S. saprophyticus,
S. xylosus, S. simulans or S. warneri
S. warneri (61.5 %), S. hominis (35.5 %) Good to genus S. warneri or S. hominisc
aMolecular identification was not deemed necessary
bThe isolate was not properly identified by biochemical methods and therefore molecular identification was required
cFurther identification to the exact Staphylococcus sp. using molecular methods was required
dContradictory identification results using biochemical methods necessitate the use of molecular identification
Zeitoun et al. BMC Microbiology  (2015) 15:275 Page 5 of 13
band size (174 bp) (Fig. 1) and were thus identified as S.
epidermidis. The results of the PCR-based identification
of these 2 isolates were in agreement with those of con-
ventional biochemical tests, while they contradicted
those of the API Staph kit.
The remaining 3 staphylococci (isolates 17, 44 and 62)
were not definitively identified by biochemical methods
(Table 2), though the API Staph kit results were more
useful in guiding us towards choosing the specific
primers (S. warneri and S. hominis-specific primers)
used in the PCR-based identification. The 3 isolates were
identified as S. warneri, since they showed a PCR prod-
uct at the expected band size (about 850 bp) upon using
the respective species-specific primer pair (Additional
file 3).
For further identification of all of the 16 Bacillus iso-
lates, three species-specific primer pairs were used, each
was respectively specific to one of the 3 most pathogenic
Bacillus spp.; B. anthracis, B. subtilis and B. cereus.
None of the Bacillus isolates was identified as B. anthra-
cis, while twelve isolates yielded a PCR product at the
specified band size (1027 bp) after PCR amplification
using a B. subtilis-specific primer pair (Additional files 4
and 5). It is worth mentioning that, although isolate 8B
failed to hydrolyse starch when grown on starch agar
and isolate 29 showed a negative Voges Proskauer test,
they were both still identified as B. subtilis using the re-
spective species-specific primer pair. Moreover, only one
Bacillus isolate (isolate 13) turned out to be B. cereus,
since it showed a PCR product at 364 bp upon using the
respective species-specific primer pair (Table 1). As for
the remaining three Bacillus isolates, none of them
showed a PCR product with any of the three used pri-
mer pairs. Consequently, the latter isolates could not be
identified by the applied PCR-based method.
The presence of three Gram-negative isolates showing
contradictory results between both conventional tests
and API 20E kit at the genus level (isolates 54A, 54B
Table 3 Identification of Gram-negative isolates using biochemical methods
Isolate
code
Identification based on conventional
biochemical tests
Identification based on API 20E kit Final conclusion
Result (%ID) Level of discrimination
1 Erwinia cacticida or Erwinia dissolvens Ent. cloacae (94.3 %) Good Contradiction
(Enterobacter/Erwinia spp.)a
8A Providencia alcalifaciens, Providencia
rustigianii or Providencia stuartii




11A Ent. aerogenes or K. pneumoniae subsp.
pneumoniae
K. pneumoniae subsp. pneumoniae (97.6 %) Good K. pneumoniae subsp.
pneumoniaea
11B Erwinia cacticida Buttiauxella agrestis (63 %) Low b
12 Erwinia cacticida or Erwinia dissolvens Ent. sakazakii (51.1 %),






54A Ent. cloacae or Ent. agglomerans K. pneumoniae subsp. pneumoniae (98 %) Good c
54B K. oxytoca Ent. sakazakii (99.9 %) Excellent c
55A Erwinia cacticida or Serratia entomophila Pantoea spp. 2 (50.7 %),
K. pneumoniae subsp. pneumoniae (30.4 %)
Low b
55B Ent. amnigenus, Ent. sakazakii or Ent.
nimipressuralis
Ent. sakazakii (98.4 %) Good Ent. sakazakiia
56 K. oxytoca Ent. sakazakii (99.9 %) Excellent c
82A Pseudomonas spp. other than P.
aeruginosa
Non fermentor spp. (32.1 %),
Ochrobactrum anthropi (25.4 %),
Bordetella/ Alcaligenes/ Moraxella spp. (24.4 %)
Low b
aMolecular identification was not deemed necessary
bThe isolate was not properly identified by biochemical methods and therefore molecular identification was required
cContradictory identification results using biochemical methods necessitate the use of molecular identification
Fig. 1 PCR amplification of specific gene fragment (174 bp) in S.
epidermidis. Lane M: 100 bp plus DNA ladder*; Lane 2: isolate 20A;
Lane 3: isolate 52; Lane 4: positive control (S. epidermidisATCC
12228); Lane 5: negative control (S. aureusATCC 6538P). * DNA
ladder yields 14 fragments of the following sizes (bp; from top to
bottom): 3000, 2000, 1500, 1200, 1000, 900, 800, 700, 600, 500, 400,
300, 200 and 100
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and 56; Table 3) necessitated the use of a PCR-based
method using Enterobacter-specific and Klebsiella-spe-
cific primer pairs. However, this was found to be in-
applicable, since the two genera share very close
genotypic characteristics [34], which was confirmed by
checking the specificity of the respective genus-specific
primer pairs published in the literature [35–37] and
using the BLAST program [23].
On the other hand, the use of the 16S rRNA universal
primer pair, followed by gene sequencing, was used
whenever biochemical identification results were incon-
clusive. This applied to; (i) two staphylococcal isolates
(16B and 22; Table 2), (ii) the Gram-positive non-spore-
forming rod-shaped isolate 24B, and (iii) three Gram-
negative isolates (11B, 55A and 82A; Table 3). Their
identification was achieved by PCR amplification of the
conserved 16S rRNA gene (~1500 bp) using a universal
primer pair, followed by DNA sequencing of the ampli-
fied 16S rRNA gene and construction of phylogenetic
trees using the BLAST program. Only three figures
representing the three groups mentioned above are
shown here (Figs. 2, 3 and 4).
The Gram-positive isolate 16B was found to bear simi-
larity to S. saprophyticus subsp. bovis (phylogenetic tree
shown in Fig. 2). This finding coincides with that of the
API Staph kit, although the latter’s results were consid-
ered “invalid” (Table 2).
Using phylogenetic analysis (Additional file 6), the
Gram-positive isolate 22 was found to be closely related
to S. warneri. Since most of S. warneri strains are known to
be mannitol-fermentors [38], while this isolate was found
to be both mannitol non-fermenting and novobiocin-
sensitive, it was incorrectly identified by conventional bio-
chemical methods as S. epidermidis. On the other hand, re-
sults of the API Staph for the same isolate showed an
invalid identification giving a %ID of 46 % and 21.3 % for S.
hominis and S. warneri, respectively (Table 2). Therefore,
the molecular identification results of the S. warneri isolate
22 somewhat agreed with those of API Staph kit; however,
they contradicted those of conventional biochemical tests.
Fig. 2 Phylogenetic tree for the Gram-positive isolate 16B
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As for the Gram-positive, non-spore-forming, rod-
shaped isolate 24B, it was found to be closely related to
Microbacterium paraoxydans by phylogenetic analysis
(Fig. 3). The identity of this isolate, which did not grow
on mannitol salt agar nor MacConkey’s agar, could not
be determined using the conventional biochemical tests.
Regarding Gram-negative isolates, the phylogenetic
tree of isolate 11B (Additional file 7) revealed a close re-
lationship to Pectobacterium cypripedii. The genus Pec-
tobacterium, which includes Gram-negative non-lactose-
fermentors, is closely related to the genus Erwinia [39].
The molecular identification result is therefore close to
that of conventional biochemical tests, which identified
this isolate as Erwinia cacticida. On the other hand, the
API 20E kit identified the same isolate, though to a low
discrimination level, as Buttiauxella agrestis (Table 3).
This result confirms the fact that the API 20E kit does
not consider lactose fermentation in the differentiation
between members of the family Enterobacteriaceae.
The phylogenetic relationship between the Gram-
negative isolate 55A and Pantoea agglomerans is illus-
trated in Fig. 4. This result was in accordance with that
of the API 20E kit that identified this isolate as Pantoea
spp. (%ID = 50.7), but with a low level of discrimination.
While K. pneumoniae subsp. pneumoniae (%ID = 30.4)
came in second place in the API kit identification, it did
not even appear in the phylogenetic tree of the isolate.
Finally, the Gram-negative isolate 82A was found to be
closely related to P. stutzeri LMG 11199T (Additional
file 8), which, in turn, is in accordance with conventional
biochemical tests, where it was identified as Pseudomonas
spp. other than P. aeruginosa (Table 3). It is noteworthy
that this isolate was not conclusively identified by the API
20E system where it was merely described as a non-
Fig. 3 Phylogenetic tree for the Gram-positive isolate 24B
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fermentor species with %ID = 32.1,and a low discrimin-
ation level.
Artificial contamination of pharmaceutical samples
Biochemical methods for detecting bacterial contami-
nants in the pharmaceutical samples involved streaking
onto selective/differential agar media for isolation of the
target microorganisms. Representative well-isolated bac-
terial colonies were then transferred to TSA plates for
further morphological and biochemical confirmatory
identification tests. The standard strains S. aureus ATCC
6538P and E. coli NCTC 10418 were subjected to bio-
chemical analysis using the API identification system. S.
aureus was misidentified as S. xylosus with a good iden-
tification level, probably due to the fact that the API
Staph kit does not include the coagulase test. On the
other hand, E. coli was correctly identified using the API
20E kit, with a very good identification level.
In our study, DNA extraction was achieved by boiling,
as suggested by Jimenez et al. [40], since that method
was found to be effective for all of the tested bacterial
contaminants. The specificity of the different previously
reported DNA primer pairs used was confirmed using a
BLAST search [41], available through the website of the
National Centre for Biotechnology Information (NCBI).
The working concentration of the primer pairs specific
to P. aeruginosa, E. coli and S. aureus used in PCR was
10 picomoles/μl. However, the S. enterica-specific primer
pair was used at a higher concentration (20–100 pico-
moles/μl), in order to show a PCR product.
All of the tested bacterial contaminants were success-
fully detected in their respective glucose samples by PCR
amplification of respective characteristic DNA fragments
using species-specific primer pairs (Fig. 5). It should be
noted that the PCR product of S. enterica was more in-
tense when using the primer pair at a higher concentra-
tion (100 picomoles/μl); however, a strong primer dimer
band was detected.
A period of 5–7 days was required for the bacteria to
be isolated, purified, and identified by biochemical
methods. On the other hand, the time needed to complete
the PCR assay, including both sample preparation and
Fig. 4 Phylogenetic tree for the Gram-negative isolate 55A
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PCR amplification of the specific DNA bacterial targets,
was only 29–30 h.
The calculated cost of each method included all the
steps required to achieve final identification of the se-
lected bacterial contaminants. However, it should be
noted that the cost of equipment required for each
method was not included. It was found that the cost of
culture media, reagents and kits required for the identifi-
cation of the selected bacterial contaminants by bio-
chemical methods in 4 samples mount to about 373
Egyptian Pounds (L.E.). On the other hand, the cost of
the reagents and chemicals required for the PCR-based
assay was about 22.7 L.E. for all 4 samples. Although the
individual reagents for the PCR assay are relatively more
expensive, they are much less in number.
We then estimated the MDL for each identification
method under investigation by inoculating 10 % glucose
solutions with different inocula (CFU/ml) of the stand-
ard E. coli NCTC 10418. On one hand, the inoculated
glucose samples were streaked onto selective agar media
as well as TSA plates to determine the least inoculum
exhibiting growth. On the other hand, the minimum in-
oculum showing a detectable PCR band of the specified
size on agarose gel was determined by pelleting 1 ml of
each inoculated glucose sample and using the pellet as a
source of DNA (by heating at 95 °C for 10 min), in order
to exclude the effect of the DNA extraction step on the
determination of the MDL of the PCR-based method.
We found that the MDL of E. coli using the PCR
assay (104 CFU/ml of sample) was lower than that
observed when using conventional methods (105 CFU/ml
of sample).
Discussion
Microbial contamination of pharmaceuticals may arise
during manufacturing, storage or use by the consumer,
and can ultimately result in several undesirable conse-
quences. In Egypt, microbiological labs follow the USP
and BP recommendations for testing the presence/load
of microbial contaminants in non-sterile dosage forms
and dietary supplements.
In the present study, different biochemical (conven-
tional and API) and molecular (PCR-based) methods
were used for the identification of a number of bacterial
contaminants isolated from various types of pharmaceu-
ticals (including pharmaceutical preparations, cosmetic
preparations, herbal products and raw materials). Both
of these methods were then compared with regard to
the recovery and identification of selected bacterial
contaminants.
The bacterial contaminants were isolated from 31 out
of 85 pre-used pharmaceutical products tested (36.5 %).
Similarly, it was reported earlier that 50% of the nonster-
ile pharmaceuticals products tested were heavily con-
taminated [42]. On the other hand, Campana et al. [1]
reported much lower contamination of the tested cos-
metic products (10.6 %). Pre-used products were chosen
for this study, in order to increase the probability of
finding contaminants. Contaminants isolated from
pharmaceutical preparations, cosmetics and raw mate-
rials were mostly Gram-positive (~90.5 %, 19 out of 21
contaminants), while those isolated from herbal products
were mostly Gram-negative (90 %, 9 out of 10 contami-
nants). In agreement with this latter finding, Abba et al.
reported that 46.67 % of herbal remedies tested were
contaminated with S. typhi, 19.33 % with Shigella spp.
and 58.67 % with E. coli [43]. The observed contamin-
ation of herbal tea bags in this study with Gram-
negative bacteria could be due to any of the following
reasons: (i) unsuitable preparation methods; (ii) contami-
nated materials and equipment; and/or (iii) improper
handling of raw materials by infected personnel during
processing. In order for herbal preparations to maintain
best quality, safety and efficacy, manufacturing compan-
ies must ensure the highest level of hygiene during
manufacturing, in order to ensure the lowest possible
level of pathogenic organisms in their final herbal prod-
ucts. On the other hand, incidents of microbial contam-
ination of cosmetics are widely reported [44–46]. This
could be attributed to inadequate preservation of cos-
metics or the use of expired products by the public,
which in turn can lead to microbial contamination that
favors growth and proliferation of skin pathogens upon
use [47]. In 2003, Hugbo and colleagues reported that
Fig. 5 PCR amplification of specific gene fragments in selected
strains. PCR amplification products of the oprL gene fragment
(500bp) in P. aeruginosa ATCC 9027 (Lane 1); uidA gene fragment
(147 bp) in E. coli NCTC 10418 (Lane 2); nucA gene fragment
(280 bp) in S. aureus ATCC 6538P (Lane 3) and invA gene fragment
(275 bp) in Sal. enterica ATCC 14028 using 20 picomoles/μL and 100
picomoles/μL species-specific primer pair, respectively. Lane M
shows 100 bp plus DNA ladder of fragments sizes (bp; from top to
bottom): 3000, 2000, 1500, 1200, 1000, 900, 800, 700, 600, 500, 400,
300, 200 and 100
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microbial contamination was detected in some brands
of cosmetic creams, where the most common bacter-
ial contaminants found were Staphylococcus spp. and
Bacillus spp., a finding which is similar to ours in the
current study [48]. On the other hand, a recent study
conducted on non-sterile oral dosage forms found
that contaminants were mostly Gram-negative entero-
bacteria [49].
Compared to cosmetics and pharmaceutical prepara-
tions, raw materials showed a higher percentage of con-
tamination (58.8 %), probably due to the lack of effective
chemical preservation, where 100 % of the contaminants
where Gram-positive bacteria. Our results are in agree-
ment with those of De Clerck et al. who reported that
the majority of contaminants isolated from gelatin ex-
tracts belonged to members of the genus Bacillus [26].
In the current study, 39 % of the contaminants were
identified as Bacillus spp., the majority of which were
isolated from non-sterile dosage forms. Similarly, in a re-
cent study from the year 2010, Mugoyela and Mwam-
bete [42] reported that the majority of microbial
contaminants isolated from non-sterile pharmaceuticals
were Bacillus spp.,
Since only 26.8 % of the isolated contaminants (6
Gram-positive and 5 Gram-negative isolates) were con-
clusively identified using both conventional methods and
the API Staph/API 20E system, molecular identification
was deemed necessary for the remaining contaminants.
In addition, further identification of Bacillus contami-
nants to their exact species was not feasible by conven-
tional biochemical tests, since members of the genus
Bacillus exhibit a wide range of physiologic versatility,
allowing them to live in almost every natural environ-
ment [26, 50]. They therefore required further identifica-
tion using PCR-based methods using species-specific
primer pairs. Similar to conventional biochemical test
results, isolates 20A and 52 showed a PCR product at
the corresponding band size (174 bp), and were thus
identified as S. epidermidis. It should be noted that iso-
late 20A was mistakenly identified as S. auricularis
using the API Staph kit. Although S. auricularis is bio-
chemically similar to S. epidermidis, the former is
urease-negative [38]. This observed contradiction in
the biochemical identification results of isolate 20A
most probably arose due to the fact that it gave a posi-
tive urease test using the conventional method,
whereas it was reported as urease-negative using the
API Staph kit. S. chromogenes also has a similar bio-
chemical profile to S. epidermidis; however, isolate 52
was not identified as S. chromogenes, since the latter pro-
duces yellow-pigmented colonies upon culturing on nutri-
ent agar [51], unlike isolate 52.
Some identification schemes do not account for
phenotypic variations among strains belonging to the
same species. For instance, S. saprophyticus is listed in
several identification schemes as mannitol non-
fermenting, although in our study, one mannitol-
fermentor, isolate 16B, was conclusively identified as S.
saprophyticus by phylogenetic analysis. On the other
hand, most of S. warneri strains are known to be manni-
tol-fermentors [38]. This fact resulted in the erroneous
identification of the S. warneri isolate 22, a mannitol non-
fermentor, novobiocin-sensitive and urease-positive
staphylococcal isolate, as S. epidermidis by conventional
biochemical methods. Nevertheless, all five S. epidermidis
isolates (16A, 20A, 20B, 52, 57A) were conclusively
identified as such by conventional biochemical tests,
based on their mannitol non-fermenting, coagulase-
and DNAse-negative, novobiocin-sensitive and urease-
positive characteristics.
In this study, both biochemical and PCR-based
methods were used to detect bacterial indicators in
artificially-contaminated pharmaceutical grade glu-
cose powder, for the purpose of comparing both
identification methods with respect to time and cost.
Optimization of the PCR reaction conditions for the
different primer pairs (annealing temperature: 55°C;
extension time: 45 s) was done in the PCR-based
identification method, in an attempt to save time. .
The PCR reaction conditions optimized in other
similar studies [29, 33] differed, probably depending
on the primer pairs used and the size of the ampli-
cons produced besides the type of DNA polymerase
used for amplification.
The relatively long time required by biochemical
methods of identification was similar to other studies
[3, 10, 33, 52]. We therefore concluded that the
standard USP procedure [53], which relies primarily
on biochemical methods for the identification of bac-
terial indicators, was both time-consuming and labor-
intensive. It also requires multiple steps for the growth
and isolation of pure bacterial cultures prior to their iden-
tification, resulting in delaying the release of raw mate-
rials/pharmaceutical products. On the other hand, the
relatively short time necessary to conduct a PCR assay
was in accordance with previous studies [33, 52]. On esti-
mating the MDL for each identification method, the MDL
of E. coli using the PCR assay was lower than that ob-
served using conventional methods. Similarly, Jimenez et
al. [54] calculated a MDL of 104 CFU/ml for Salmonella
spp. by a PCR-based method, while a year later, a higher
MDL (105 CFU/ml) for E. coli, P. aeruginosa and S. aureus
was reported [40]. Conversely, Samadi et al. [55] reported
a much lower MDL of 102 CFU/ml. More recently, Faraj-
nia et al. [52] were able to detect microbial contamination
at a level of less than 10 CFU/ml or gram of a product,
using a multiplex PCR assay. None of the latter studies
calculated an MDL for conventional tests.
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Conclusion
PCR-based methods provided an earlier, more cost-effective
and more sensitive detection and identification of bacterial
contamination, compared to standard biochemical methods
currently applied in the pharmaceutical industry. This
would allow for rapid implementation of corrective actions,
thereby minimizing manufacturing losses and speeding up
product release.
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